Elsevier said this week that it has acquired the business assets of Ariadne Genomics for an undisclosed sum.

Under its new ownership, the Rockville, Md.-based pathway analysis firm will be integrated with Elsevier's corporate markets division, the publishing firm said.

Alexander van Boetzelaer, Elsevier's managing director of corporate markets, said that Ariadne's product portfolio provides "a powerful complement" to his firm's existing "chemistry, pre-clinical and clinical workflow solutions."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.

May
28
Sponsored by
PerkinElmer

This online seminar will demonstrate how RNA-seq analysis in a model organism can provide insights into human disease.